Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics
Emergent Biosolutions, Inc. (EBS)
Today's Latest Price: $79.67 USD
Updated Nov 23 6:40pm
Add EBS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
EBS Stock Summary
- EBS has a market capitalization of $4,380,908,830 -- more than approximately 74.51% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Emergent BioSolutions Inc is reporting a growth rate of 448.56%; that's higher than 96.73% of US stocks.
- Revenue growth over the past 12 months for Emergent BioSolutions Inc comes in at 31.13%, a number that bests 84.84% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Emergent BioSolutions Inc are ACLS, FORM, NVMI, SRNE, and ERII.
- Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.
EBS Stock Price Chart Interactive Chart >
EBS Price/Volume Stats
| Current price | $79.67 | 52-week high | $137.61 |
| Prev. close | $82.66 | 52-week low | $46.37 |
| Day low | $77.73 | Volume | 690,500 |
| Day high | $83.77 | Avg. volume | 645,185 |
| 50-day MA | $96.50 | Dividend yield | N/A |
| 200-day MA | $86.20 | Market Cap | 4.22B |
Emergent Biosolutions, Inc. (EBS) Company Bio
Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
EBS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $79.67 | $124.34 | 50% |
Below please find a table outlining a discounted cash flow forecast for EBS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Emergent BioSolutions Inc ranked in the 56th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 51%. In terms of the factors that were most noteworthy in this DCF analysis for EBS, they are:
- Interest coverage, a measure of earnings relative to interest payments, is 8.13 -- which is good for besting 65.77% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- Emergent BioSolutions Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.74% of tickers in our DCF set.
- Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 19 -- greater than 76.27% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 47% |
| 1% | 49% |
| 2% | 50% |
| 3% | 52% |
| 4% | 53% |
| 5% | 55% |
HRC, MCK, DXCM, PRAH, and ACIU can be thought of as valuation peers to EBS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...